Oral @entity230 and XXXX during endoscopic sinus surgery.

@entity1 @entity548 @entity190 @entity228 @entity4421 @entity954 @entity230 @entity480 @entity617 @entity288
OBJECTIVES: Our main objective was to investigate the effect of preoperative oral @entity230 on @entity954 and quality of the surgical field during endoscopic sinus surgery (ESS). Our second objective was to determine whether the @entity4421 score could be used to predict the volume of @entity954 . METHODOLOGY: This double-blinded, randomized trial included 65 @entity1 with chronic rhinosinusitis with @entity480 . The @entity228 group received oral @entity617 (1 mg/kg), administered to @entity1 once daily for 2 days and then tapered down, with treatment completed on the day 10. The control group received placebo before the operation. Endoscopic exams were recorded, and preoperative sinus computed tomography scans were scored. Intraoperative @entity190 was recorded. Quality of the surgical field was assessed by the surgeon, using a linear scale from 1 to 10. RESULTS: The mean @entity548 volume was 239 ml in the @entity228 group and 203 ml in control group. There was no significant difference between the groups (p = 0.495). Surgical field quality scores were higher in the @entity228 group than in the control group, but the difference was not significant (p = 0.36). There was no statistically significant relationship between the @entity548 volume and Kennedy @entity4421 Scores in @entity228 group (r = 0.225, p = 0.186) and control group (r = 0.084, p = 0.663). CONCLUSION: Our findings suggest that using oral @entity288 , which have rare but serious side effects, is not necessary in the preoperative period. Furthermore, we found that the radiological @entity4421 score was not a suitable marker for predicting @entity954 volumes.
